Publications
- Genetic and Proteomic Features Associated with Survival after treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503
- VeriStrat Classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.
- Mass Spectrometry to Classify Non-Small Cell Lung Cancer Patients for Clinical Outcome After
Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort
Cross-Institutional Study.
- Quantitative matrix-assisted laser desorption/ionization mass spectrometry.
2008 ASCO Abstracts
- Changes in serum proteomic profile of non-small cell lung cancer (NSCLC) patients during therapy with epidermal growth factor receptor tirosine kinase inhibitors (EGFR-TKIs): Preliminary report.
- Predictive value of serum MALDI-TOF proteomic profiling from patients treated with erlotinib and bevacizumab for survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib alone.
2009 ASCO Abstracts
- Mass spectrometry profile as a predictor of overall survival benefit after treatment with epidermal growth factor receptor inhibitors in head and neck squamous cell carcinoma.
- Genetic and proteomic features associated with survival after treatment with erlotinib in first line therapy of non-small cell lung cancer.